Ectopic Expression of CCL19 Impairs Alloimmune Response in Mice

Overview

Journal Immunology

Specialty Allergy & Immunology

Date 2004 May 19

PMID 15147573

Citations 8

Authors

Stefan Krautwald

Ekkehard Ziegler

Reinhold Forster

Lars Ohl

Kerstin Amann

Ulrich Kunzendorf

Affiliations

Soon will be listed here.

Abstract

Initiation of an antitumour immune response is characterized by a complex process of chemokine-mediated cell migration and cell-cell interactions. Overexpression of chemokine CCL19 in tumour cells has been shown to result in accelerated tumour rejection under certain experimental conditions, suggesting a novel approach in the therapy of neoplastic malignancies. To investigate CCL19-mediated modulations of cellular immune responses in vivo, we generated a chimeric CCL19-immunoglobulin G2b (IgG2b) Fc fusion protein, which binds to the chemokine receptor CCR7 comparable to native CCL19. CCL19-IgG2b possesses a long-lasting potent chemotactic activity as a result of the extended half-life of Fc fusion proteins. Stable overexpression of CCL19-IgG2b in BALB/c-derived J558L tumour cells fails to support tumour cell rejection following transplantation in syngeneic mice. Moreover, overexpression of CCL19-IgG2b hinders tumour rejection in allogeneic C57BL/6 mice. This phenomenon was accompanied by a six-fold increase of dendritic cells (DCs) isolated from CCL19-IgG2b-secreting tumours when compared to the number of DCs isolated from control parental J558L tumours. While mice bearing the allogeneic parental tumour showed an intense hypercellularity in the draining lymph nodes, no such response could be observed in the draining lymph nodes of mice carrying the CCL19-IgG2b-secreting tumour. We could demonstrate that overexpression of CCL19-IgG2b in tumour cells retains antigen-presenting cells in the tumour mass and prevents DCs from migrating into draining lymph nodes to present antigens and to activate T cells, resulting in an impaired immune response against the tumour.

Citing Articles

Haptoglobin Induces a Specific Proteomic Profile and a Mature-Associated Phenotype on Primary Human Monocyte-Derived Dendritic Cells.

Torres A, Vivanco S, Lavin F, Pereda C, Chernobrovkin A, Gleisner A Int J Mol Sci. 2022; 23(13).

PMID: 35805888 PMC: 9266681. DOI: 10.3390/ijms23136882.

Investigation of Fascin1, a Marker of Mature Dendritic Cells, Reveals a New Role for IL-6 Signaling in CCR7-Mediated Chemotaxis.

Matsumura F, Polz R, Singh S, Matsumura A, Scheller J, Yamashiro S J Immunol. 2021; 207(3):938-949.

PMID: 34301846 PMC: 8360331. DOI: 10.4049/jimmunol.2000318.

Melanoma cell lysate induces CCR7 expression and in vivo migration to draining lymph nodes of therapeutic human dendritic cells.

Gonzalez F, Ortiz C, Reyes M, Dutzan N, Patel V, Pereda C Immunology. 2014; 142(3):396-405.

PMID: 24673602 PMC: 4080955. DOI: 10.1111/imm.12264.

Comparative modeling of CCRL1, a key protein in masked immune diseases and virtual screening for finding inhibitor of this protein.

Behjati M, Torktaz I, Mohammadpour M, Ahmadian G, Easton A Bioinformation. 2012; 8(7):336-40.

PMID: 22553392 PMC: 3338979. DOI: 10.6026/97320630008336.

Intratumoral administration of secondary lymphoid chemokine and unmethylated cytosine-phosphorothioate-guanine oligodeoxynucleotide synergistically inhibits tumor growth in vivo.

Oh S, Oh K, Lee D J Korean Med Sci. 2011; 26(10):1270-6.

PMID: 22022177 PMC: 3192336. DOI: 10.3346/jkms.2011.26.10.1270.

References

Arenberg D, Zlotnick A, Strom S, Burdick M, Strieter R . The murine CC chemokine, 6C-kine, inhibits tumor growth and angiogenesis in a human lung cancer SCID mouse model. Cancer Immunol Immunother. 2001; 49(11):587-92. PMC: 11037015. DOI: 10.1007/s002620000147. View

Forster R, Schubel A, Breitfeld D, Kremmer E, Renner-Muller I, Wolf E . CCR7 coordinates the primary immune response by establishing functional microenvironments in secondary lymphoid organs. Cell. 1999; 99(1):23-33. DOI: 10.1016/s0092-8674(00)80059-8. View

Bardi G, Lipp M, Baggiolini M, Loetscher P . The T cell chemokine receptor CCR7 is internalized on stimulation with ELC, but not with SLC. Eur J Immunol. 2001; 31(11):3291-7. DOI: 10.1002/1521-4141(200111)31:11<3291::aid-immu3291>3.0.co;2-z. View

Kirk C, Mule J . The dynamics of the T-cell antitumor response: chemokine-secreting dendritic cells can prime tumor-reactive T cells extranodally. Cancer Res. 2001; 61(24):8794-802. View

Budde K, Schmouder R, Brunkhorst R, Nashan B, W Lucker P, Mayer T . First human trial of FTY720, a novel immunomodulator, in stable renal transplant patients. J Am Soc Nephrol. 2002; 13(4):1073-1083. DOI: 10.1681/ASN.V1341073. View

Chomczynski P, Sacchi N . Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 1987; 162(1):156-9. DOI: 10.1006/abio.1987.9999. View

Hock H, Dorsch M, Kunzendorf U, Qin Z, DIAMANTSTEIN T, Blankenstein T . Mechanisms of rejection induced by tumor cell-targeted gene transfer of interleukin 2, interleukin 4, interleukin 7, tumor necrosis factor, or interferon gamma. Proc Natl Acad Sci U S A. 1993; 90(7):2774-8. PMC: 46178. DOI: 10.1073/pnas.90.7.2774. View

Qin Z, Kruger-Krasagakes S, Kunzendorf U, Hock H, DIAMANTSTEIN T, Blankenstein T . Expression of tumor necrosis factor by different tumor cell lines results either in tumor suppression or augmented metastasis. J Exp Med. 1993; 178(1):355-60. PMC: 2191077. DOI: 10.1084/jem.178.1.355. View

Lyons A, Parish C . Determination of lymphocyte division by flow cytometry. J Immunol Methods. 1994; 171(1):131-7. DOI: 10.1016/0022-1759(94)90236-4. View

10.

Schweickart V, Raport C, Godiska R, Byers M, Eddy Jr R, Shows T . Cloning of human and mouse EBI1, a lymphoid-specific G-protein-coupled receptor encoded on human chromosome 17q12-q21.2. Genomics. 1994; 23(3):643-50. DOI: 10.1006/geno.1994.1553. View

11.

Zheng X, Steele A, Nickerson P, Steurer W, Steiger J, Strom T . Administration of noncytolytic IL-10/Fc in murine models of lipopolysaccharide-induced septic shock and allogeneic islet transplantation. J Immunol. 1995; 154(10):5590-600. View

12.

Sullivan S, McGrath D, Liao F, Boehme S, Farber J, Bacon K . MIP-3alpha induces human eosinophil migration and activation of the mitogen-activated protein kinases (p42/p44 MAPK). J Leukoc Biol. 1999; 66(4):674-82. DOI: 10.1002/jlb.66.4.674. View

13.

Braun S, Chen K, Foster R, Kim C, Hromas R, Kaplan M . The CC chemokine CK beta-11/MIP-3 beta/ELC/Exodus 3 mediates tumor rejection of murine breast cancer cells through NK cells. J Immunol. 2001; 164(8):4025-31. DOI: 10.4049/jimmunol.164.8.4025. View

14.

Sharma S, Stolina M, Luo J, Strieter R, Burdick M, Zhu L . Secondary lymphoid tissue chemokine mediates T cell-dependent antitumor responses in vivo. J Immunol. 2000; 164(9):4558-63. DOI: 10.4049/jimmunol.164.9.4558. View

15.

Vicari A, Chemin K, Mueller A, Zlotnik A, Caux C . Antitumor effects of the mouse chemokine 6Ckine/SLC through angiostatic and immunological mechanisms. J Immunol. 2000; 165(4):1992-2000. DOI: 10.4049/jimmunol.165.4.1992. View

16.

Luther S, Tang H, Hyman P, Farr A, Cyster J . Coexpression of the chemokines ELC and SLC by T zone stromal cells and deletion of the ELC gene in the plt/plt mouse. Proc Natl Acad Sci U S A. 2000; 97(23):12694-9. PMC: 18826. DOI: 10.1073/pnas.97.23.12694. View

17.

Lipp M, Forster R, Schubel A, Burgstahler R, Muller G, Breitfeld D . Functional organization of secondary lymphoid organs by homeostatic chemokines. Eur Cytokine Netw. 2001; 11(3):504-5. View

18.

Kunzendorf U, Pohl T, Bulfone-Paus S, Krause H, Notter M, Onu A . Suppression of cell-mediated and humoral immune responses by an interleukin-2-immunoglobulin fusion protein in mice. J Clin Invest. 1996; 97(5):1204-10. PMC: 507172. DOI: 10.1172/JCI118534. View

19.

Yoshida R, Imai T, Hieshima K, Kusuda J, Baba M, Kitaura M . Molecular cloning of a novel human CC chemokine EBI1-ligand chemokine that is a specific functional ligand for EBI1, CCR7. J Biol Chem. 1997; 272(21):13803-9. DOI: 10.1074/jbc.272.21.13803. View

20.

Rollins B . Chemokines. Blood. 1997; 90(3):909-28. View